2023
Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodes
2014
The international normalized ratio overestimates coagulopathy in patients after major hepatectomy
Louis S, Barton J, Riha G, Orloff S, Sheppard B, Pommier R, Underwood S, Differding J, Schreiber M, Billingsley K. The international normalized ratio overestimates coagulopathy in patients after major hepatectomy. The American Journal Of Surgery 2014, 207: 723-727. PMID: 24791634, DOI: 10.1016/j.amjsurg.2013.12.021.Peer-Reviewed Original ResearchConceptsInternational normalized ratioMajor hepatectomyNormalized ratioPatient populationElevated international normalized ratioUse of thrombelastographyPostoperative day 1Postoperative time pointsHypercoagulable statePreoperative valuesDecreased incidenceProcoagulant factorsTEG measurementsCoagulation factorsDay 1ThrombelastographyHepatectomyFactor VIIISubsequent normalizationPatientsTime pointsHypocoagulabilityTherapyProtein C.
2013
Coagulopathy after a liver resection: is it over diagnosed and over treated?
Barton J, Riha G, Differding J, Underwood S, Curren J, Sheppard B, Pommier R, Orloff S, Schreiber M, Billingsley K. Coagulopathy after a liver resection: is it over diagnosed and over treated? Hepato Pancreato Biliary 2013, 15: 865-871. PMID: 23458574, PMCID: PMC4503284, DOI: 10.1111/hpb.12051.Peer-Reviewed Original ResearchConceptsProthrombin time-international normalized ratioPost-operative time pointsLiver resectionPost-operative day 1Initiation of thromboprophylaxisLiver resection patientsNormal coagulation functionTime pointsPT-INR valuesTime of onsetProphylactic anticoagulationElective hepatectomyResection patientsPlasma transfusionHypercoagulable stateAnesthetic techniqueCoagulation functionNormalized ratioPlasma therapyPringle manoeuverRelative hypercoagulabilityFunctional assessmentDay 1ResectionThrombelastography
2011
Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases
Hammill C, Billingsley K, Cassera M, Wolf R, Ujiki M, Hansen P. Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases. Annals Of Surgical Oncology 2011, 18: 1947-1954. PMID: 21399885, DOI: 10.1245/s10434-010-1535-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedCatheter AblationCohort StudiesColorectal NeoplasmsCombined Modality TherapyFemaleFollow-Up StudiesHumansLaparoscopyLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPreoperative CareProspective StudiesRetrospective StudiesSurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsColorectal liver metastasesLaparoscopic radiofrequency ablationResectable colorectal liver metastasesRadiofrequency ablationResectable groupHepatic resectionLiver metastasesUnresectable groupMedian disease-free survivalComparable long-term survivalOutcomes of patientsDisease-free survivalKaplan-Meier methodLog-rank testLong-term survivalDiagnostic imaging studiesFavorable morbidityCRLM patientsPostoperative mortalityUnresectable diseaseMajor complicationsTumor numberResultsA totalSurgical oncologistsOutcome data
2010
Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors
Ellis M, Cassera M, Vetto J, Orloff S, Hansen P, Billingsley K. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. Hepato Pancreato Biliary 2010, 13: 59-63. PMID: 21159105, PMCID: PMC3019543, DOI: 10.1111/j.1477-2574.2010.00242.x.Peer-Reviewed Original ResearchConceptsOverall survival rateIntrahepatic cholangiocarcinomaR0 resectionSurgical treatmentR1/R2 resectionResectable intrahepatic cholangiocarcinomaPostoperative liver failureMainstay of treatmentOptimal patient selectionPostoperative complication rateKaplan-Meier methodCox hazard modelPreoperative hypoalbuminaemiaReplete patientsR2 resectionSurgical mortalityComplication rateSurgical resectionSurgical therapyWorse survivalClinicopathologic characteristicsLiver failureOperative detailsPrognostic factorsRecurrence outcomes
2004
Uncommon anal neoplasms
Billingsley K, Stern L, Lowy A, Kahlenberg M, Thomas C. Uncommon anal neoplasms. Surgical Oncology Clinics Of North America 2004, 13: 375-388. PMID: 15137963, DOI: 10.1016/j.soc.2003.12.002.Peer-Reviewed Original ResearchConceptsAnal neoplasmsClinical trialsProspective phase II clinical trialPhase II clinical trialPatient care algorithmsSurgeons Oncology GroupOncology GroupCare algorithmTreatment algorithmClinical trial datasetAmerican CollegeSurgical pathologyNeoplasmsTrial datasetTechnique guidelinesTrialsPathologyEndpointAnus